According to Bloomberg.com, the seven rating agencies currently monitoring the stock have given the stock of Selecta Biosciences, INC (NASDAQ: SELB) an average rating of “buy,” which indicates that investors should purchase the stock.
This information was gathered from rating agencies that are currently monitoring the stock. Six experts in the field have each analyzed the stock, and all have recommended purchasing it.
Most brokerage firms that rated the company in the previous year have projected that they will achieve a price target of $6.00 within the next twelve months.
This projection comes from looking at the company’s historical performance.
Over the most recent few years, there has been an explosion of research articles centered on SELB. HC Wainwright increased the price objective for Selecta Biosciences from $4.00 to $5.00 in a research note made public on Wednesday.
The previous price objective was $4.00. Selecta Biosciences received a rating of “buy” from the company, and the company suggested that investors purchase the company’s stock.
In a research report published on January 31, Canaccord Genuity Group lowered both their “buy” rating for Selecta Biosciences and their target price.
The price at which success would be achieved was reduced from $10.00 to $9.00. On March 13, 2019, StockNews.com switched its recommendation for Selecta Biosciences from “hold” to “buy” on the market.
In a study released on Wednesday, Mizuho lowered their “buy” recommendation and target price for Selecta Biosciences from $5 to $4.
The target price remained the same. Needham & Company LLC maintained its “buy” rating on shares of Selecta Biosciences and set a target price of $5.00 for the company’s stock in a research report released on Tuesday.
Thursday was NASDAQ’s first day: SELB was available for trading, and the opening price was $1.41.
All of the liquidity ratios, including the current, quick, and debt-to-equity ratios, total 5.91, while the debt-to-equity ratio is at 0.19. Over the last 52 weeks, the price of a share of Selecta Biosciences has ranged from $0.65 to $2.73, with a price of $2.73 serving as the average.
The current P/E ratio for the company is 10.85, and it has a beta value of 1.17.
The market capitalization of the company is $216.18 million.
The stock has traded at a moving average price of $1.53 over the past 200 trading days, while the stock has traded at a moving average price of $1.65 over the last fifty trading days.
The financial report for Selecta Biosciences, which is traded on the NASDAQ using the ticker symbol SELB, was made public on March 2.
The quarterly earnings per share came in at $0.03, $0.01 higher than analysts’ consensus estimate of $0.04.
In other words, the actual earnings were better than expected by $0.01.
The company’s sales for the quarter came in at $16.80 million, which is considerably higher than the analysts’ predictions of $12.72 million, which were significantly below the actual amount. Selecta Biosciences had a return on equity of 15.67% and a net margin of 31.94% for the business.
The projections made by industry professionals in the field of research indicate that Selecta Biosciences will report a loss of $0.41 per share in 2018.
Carsten Brunn, the company’s Chief Executive Officer, completed a transaction on January 4, 2013, in which he sold 27,597 shares of the company’s stock.
This is another piece of news related to this topic.
The stock was sold for a total price equivalent to $1.13 per share during the transaction.
This price came to a total of $31,184.61.
The transaction has been finalized, and as a result, the CEO now owns 799,486 shares of the company’s stock.
Based on the current market price, these shares have a value of approximately $903,419.18. You will be taken to a filing made with the Securities and Exchange Commission if you click on the link provided for you, where you will be able to obtain additional information regarding the sale.
The corporation’s insiders own 30.50 percent of the total number of outstanding shares.
Many institutional investors and hedge funds have recently bought and sold SELB stock.
During the second quarter, Price T. Rowe Associates INC MD increased the percentage of Selecta Biosciences stock that it owned to 25.7% from the previous quarter’s level.
As a result of the purchase of an additional 4,464 shares during the most recent fiscal quarter, Price T. Rowe Associates INC, MD, now has a total of 21,810 shares of the company’s stock, valued at $29,000.
This brings the total number of shares owned by the company to 21,810.
Eqis Capital Management, INC made investments totaling approximately $30,000 over the year’s first three months to increase its ownership stake in Selecta Biosciences.
Beacon Pointe Advisors LLC spent approximately $33,000 during the first three months of 2018 to acquire a new position at Selecta Biosciences.
This investment was made in the form of a new position.
As of the end of the second quarter, Prudential Financial INC held 161.6 percent more shares of Selecta Biosciences than it did at the beginning of the period.
Prudential Financial INC now has 27,000 shares of the company’s stock after purchasing an additional 16,680 shares throughout the quarter.
Based on the price at which the company’s stock is trading on the market, the company’s stock is currently worth $35,000 to Prudential Financial INC In the final step, Virtu Finance LLC acquired a new stake in Selecta Biosciences by contributing approximately $38,000 during the third quarter.
Institutional investors and hedge funds currently control 40.25 percent of the company’s shares.
Research is conducted, and Selecta Biosciences, Inc develops nanoparticle immunomodulatory drugs.
This biopharmaceutical company is in the clinical stages of development and focuses on treating and preventing human diseases.
As a direct result, the platform known as synthetic vaccine particles (SVP) was developed; this platform is used for immune activation and tolerance.